

REMARKS

Claims 1-23 are currently pending. The sole issue is rejection of these claims under the judicially created doctrine of non-statutory obviousness-type double patenting in view of U.S. patent numbers 6,748,265. Accompanying this paper please find a terminal disclaimer (and fee), thereby obviating this rejection. As no other issues are believed to remain outstanding, entry of this terminal disclaimer should place this application in condition for allowance. Applicant accordingly requests prompt issuance of such a notice. Of course, should any other issue remain, the Examiner is encouraged to contact Applicant's undersigned attorney so that such issue(s) can be expeditiously resolved without the need for another formal action and response thereto.

Respectfully submitted,

Dated: November 29, 2007

By: 

Daniel M. Chambers
Attorney for Applicants
BioTechnology Law Group
Reg. No. 34,561